Medical News

RSS

Senate Democrats move closer to passing bill that will delay Medicare pay cut slated for doctors

MedPage Today: Senate Democrats on Wednesday won a "key vote" toward delaying a 21 percent cut in physicians reimbursements from Medicare. Those cuts officially went into effect on April 1. On a 60-40 vote, the Senate agreed to exempt a provision to delay the cuts by Sen. Max Baucus, D-Mont., "from a Senate rule that says all spending legislation must be paid for."

16 Apr 2010

Sexual minorities more likely to experience posttraumatic stress disorder

A new study from researchers at the Harvard School of Public Health (HSPH) and Children's Hospital Boston has found that gay men, lesbians, bisexuals, and heterosexuals who have ever had a same-sex sex partner are one-and-a-half to two times as likely to experience violent events, especially in childhood, than the general population.

16 Apr 2010

Many women with invasive breast cancer unaware of skin-sparing mastectomy

In the U.S., more than 180,000 women are diagnosed with invasive breast cancer each year. Many of these women will undergo mastectomy surgery that will result in disfiguring scars because they are unaware of the availability of skin-sparing mastectomies and did not ask their surgeons about this treatment option. Skin-sparing mastectomy is a surgical technique to remove cancerous breast tissue by using the same minimal and judiciously placed incisions used by plastic surgeons for elective breast surgery.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

16 Apr 2010

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).

16 Apr 2010

Illinois' tobacco tax would bring in $297.6M in new revenue, reduce youth smoking

A new poll released today finds that 74 percent of Illinois voters support raising the tobacco tax by $1 per pack to cut the state's budget deficit and reduce youth tobacco use.

16 Apr 2010

Sebelius: Plan coming to reduce minority health disparities

Health and Human Services Secretary Kathleen Sebelius said Wednesday that the federal government will soon have a national plan to reduce health disparities between minorities and whites, The Associated Press reports.

16 Apr 2010

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.

16 Apr 2010

Waxman backs away from challenge to big corporations on health costs

Kaiser Health News staff writer Christopher Weaver writes about the cancellation of an upcoming House Energy and Commerce Hearing and what it might mean: "A new congressional staff report has defused a standoff between Democrats and large corporations over losses the firms anticipate because of the new health overhaul law" (Weaver, 4/14).

16 Apr 2010

GeoViz methods help users visualize the pattern of how disease spreads

Disease statistics buried within patient records or detailed in newspaper clippings can be sorted and organized to depict geographic patterns, allowing the discovery of trends that were previously overlooked, according to a Penn State geographer.

16 Apr 2010

Researchers say exclusive licensing on genes could hurt patients

The Wall Street Journal reports that Duke University researchers have found in a study published Wednesday that granting "exclusive licenses on individual genes" could hurt patients' chances of pinpointing their risks to develop disease.

16 Apr 2010

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

The University Hospital of Zurich has become the first medical center in the world to commence treating cancer patients with the revolutionary TrueBeam system from Varian Medical Systems, a new platform for image-guided radiotherapy and radiosurgery that was designed from the ground up to treat a moving target with unprecedented speed and precision.

16 Apr 2010

Flavonoids of onion are natural alternative to artificial additives in food industry: Study

Some components of the onion have antioxidant and antimicrobial properties, making it possible to use this bulb for food preservation. This is demonstrated by researchers from the Polytechnic University of Catalu-a and the University of Barcelona in a study that has just been published in the International Journal of Food Science and Technology.

16 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Sunlight Research – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape. Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.

16 Apr 2010

Self-monitoring of Coumadin levels reduces risk of blood clots by 50%: Study

A new review of existing research finds that many patients who take an anti-clotting drug or "blood-thinner" can benefit from monitoring the levels of the drug themselves instead of going to clinics for blood tests.

16 Apr 2010

IRS official: If an individual fails to show insurance coverage, refund could be withheld

"The Internal Revenue Service won't audit you to make sure you have purchased health insurance under provisions of the new health-care law—but it may withhold your tax refund if you can't demonstrate that you are insured, an IRS official said Thursday," The Wall Street Journal reports. "There are tools we can use. We obviously will be notifying folks [for whom there is no record of health insurance] that we have these questions," Steven T. Miller, IRS deputy commissioner for services and enforcement, said.

16 Apr 2010

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

16 Apr 2010

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver Congress™ 2010, the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

16 Apr 2010

Medical News

Senate Democrats move closer to passing bill that will delay Medicare pay cut slated for doctors

Sexual minorities more likely to experience posttraumatic stress disorder

Many women with invasive breast cancer unaware of skin-sparing mastectomy

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Illinois' tobacco tax would bring in $297.6M in new revenue, reduce youth smoking

Sebelius: Plan coming to reduce minority health disparities

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Waxman backs away from challenge to big corporations on health costs

GeoViz methods help users visualize the pattern of how disease spreads

Researchers say exclusive licensing on genes could hurt patients

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

Flavonoids of onion are natural alternative to artificial additives in food industry: Study

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Self-monitoring of Coumadin levels reduces risk of blood clots by 50%: Study

IRS official: If an individual fails to show insurance coverage, refund could be withheld

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News